Even though Arvinas and Pfizer appear to have "written off" the drug, in one analyst's view, Rigel believes it can drive adoption among community-treated patients lacking SERD access.

Although the oncology community is buzzing with the potential of circulating tumor DNA (ctDNA) to revolutionize breast cancer ...

DNA liquid biopsies detect breast cancer at molecular levels to guide personalized therapy and monitor for recurrence or ...

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...

A blood test that detects tumor DNA circulating in the bloodstream may help select the most effective treatment options for ...

False-positive multi-target stool tests are linked to higher rates of noncolorectal aerodigestive cancers, suggesting further ...

Health-evidence reviewers reverse recommendation on a blood test that detects a biomarker of a common cancer after decades of ...

Emerging research suggests the state of the gut microbiome in early life is linked to colorectal cancer—and that both too ...

Genomic profiling can help personalize cancer care, but patients may not be offered these tests due to a burdensome ...

Gallbladder cancer (GBC) is an extremely aggressive biliary tract malignancy characterized by silent early progression, ...

FDA approves atezolizumab and a companion diagnostic for adjuvant treatment of MIBC in patients with detected circulating tumor DNA after surgery. The US Food and Drug Administration (FDA) has ...